Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In that respect the combination of bleomycin, vindesine (Eldesine), mitomycin C and cisplatin (BEMP) was the most promising. In the present study BEMP has been compared with the best single agent, cisplatin (P) in the expectation that improved response rates might translate into a better survival.

Vermorken, J., Zanetta, G., De Oliveira, C., van der Burg, M., Lacave, A., Teodorovic, I., et al. (2001). Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. ANNALS OF ONCOLOGY, 12(7), 967-974 [10.1023/A:1011165115426].

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study

COLOMBO, NICOLETTA
2001

Abstract

Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In that respect the combination of bleomycin, vindesine (Eldesine), mitomycin C and cisplatin (BEMP) was the most promising. In the present study BEMP has been compared with the best single agent, cisplatin (P) in the expectation that improved response rates might translate into a better survival.
Articolo in rivista - Articolo scientifico
Antibiotics, Antineoplastic; Treatment Outcome; Bleomycin; Middle Aged; Survival Analysis; Female; Uterine Neoplasms; Vindesine; Humans; Prospective Studies; Antineoplastic Agents; Europe; Mitomycin; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents, Phytogenic; Aged; Adult; Drug Administration Schedule; Carcinoma, Squamous Cell; Cisplatin
English
lug-2001
12
7
967
974
none
Vermorken, J., Zanetta, G., De Oliveira, C., van der Burg, M., Lacave, A., Teodorovic, I., et al. (2001). Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. ANNALS OF ONCOLOGY, 12(7), 967-974 [10.1023/A:1011165115426].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/26702
Citazioni
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 32
Social impact